Journal ArticleDOI
Deprenyl can induce soluble superoxide dismutase in rat striata.
Reads0
Chats0
TLDR
(−)-Deprenyl (0.25 or 2mg/kg) or saline was injected daily into male Wistar rats for 3 weeks and induced a significant increase in the soluble but not the particulate form of the enzyme.Abstract:
(−)-Deprenyl (0.25 or 2mg/kg) or saline was injected daily into male Wistar rats for 3 weeks. The striata were dissected out and soluble and particulate Superoxide dismutase activity measured. (−)-Deprenyl at 2mg/kg induced a significant increase in the soluble but not the particulate form of the enzyme. The possibility that this action contributes to the ability of (−)-deprenyl to retard nigral degeneration in man and prolong life in rats is discussed.read more
Citations
More filters
Journal ArticleDOI
Age- and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and the glutathione system
Gianni Benzi,Antonio Moretti +1 more
TL;DR: This review will focus on studies investigating the role of the electron transfer chain as the site of ROS formation in brain aging and the alterations of the glutathione system, also in relation to the effects of exogenous pro-oxidant agents.
Journal ArticleDOI
Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo
TL;DR: In this article, a modified microdialysis procedure was used to confirm that intrastriatal administration of 1-methyl-4-phenylpyridinium ion (MPP+) induced a sustained overflow of dopamine accompanied by increased formation of hydroxyl free radicals.
Journal ArticleDOI
The molecular pharmacology of L-deprenyl.
TL;DR: If selective inhibition is to be maintained in vivo, correct dosage schedules are critically important, since all selective MAO inhibitors described up to now lack selectivity at high doses.
Journal ArticleDOI
MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?
TL;DR: The biochemical and pharmacological properties of inhibitors of the monoamine oxidase type B are reviewed, including possible antioxidative and antiapoptotic activities of these agents, and the significance for the pharmacological management of Parkinson's disease is discussed.
Journal ArticleDOI
L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Karuppagounder S. Saravanan,Kizhakke M. Sindhu,Karuppagounder S. Senthilkumar,Kochupurackal P. Mohanakumar +3 more
TL;DR: In this article, the authors investigated the effect of deprenyl in neuronal death produced by intranigral infusion of a potent mitochondrial complex-I inhibitor, rotenone in rats.
References
More filters
Journal Article
Effect of deprenyl on the progression of disability in early Parkinson's disease
Ira Shoulson,S. Fahn,David Oakes,C. Odoroff,Anthony E. Lang,J. W. Langston,P. LeWitt,W. Olanow,J. B. Penney,C. Tanner,W. Koller,Robert L. Rodnitzky,J. S. Fink,J. H. Growdon,G. Paulson,Roger Kurlan,Joseph H. Friedman,S. Gancher,J. Nutt +18 more
TL;DR: It is concluded from these preliminary results that the use of deprenyl (10 mg per day) delays the onset of disability associated with early, otherwise untreated cases of Parkinson's disease.
Journal ArticleDOI
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
JW Tetrud,J. W. Langston +1 more
TL;DR: Early deprenyl therapy delays the requirement for antiparkinsonian medication, possibly by slowing progression of the disease.
Journal ArticleDOI
A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra.
TL;DR: Increased activity of SOD in particulate fraction may be a protective response to elevated levels of toxic free radicals in the parkinsonian substantia nigra, and increased SOD activity may induce cell death through the accumulation of hydrogen peroxide.
Journal ArticleDOI
Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study
TL;DR: Results are interpreted as indicating l-deprenyl's ability to prevent or retard the degeneration of striatal dopaminergic neurons, the first anti-Parkinson drug having such a property.
Journal ArticleDOI
Dopamine is a monoamine oxidase B substrate in man
TL;DR: It is demonstrated that, as far as DA oxidation is concerned, man may be different from rat: in two sites the authors have investigated, platelet and brain, DA is preferentially deaminated by an enzyme with the characteristics of MAOB.
Related Papers (5)
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
JW Tetrud,J. W. Langston +1 more